STOCK TITAN

Axsome Therapeutics, Inc. - $AXSM STOCK NEWS

Welcome to our dedicated page for Axsome Therapeutics news (Ticker: $AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics stock.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a leading biopharmaceutical company dedicated to developing innovative therapies for the treatment of central nervous system (CNS) disorders. Headquartered in New York City, Axsome's mission is to address unmet medical needs and improve the lives of patients suffering from CNS conditions.

The company's portfolio includes a mix of clinical-stage and research-stage product candidates, with a primary focus on CNS disorders such as depression, migraine, narcolepsy, and Alzheimer's disease. Axsome's pipeline features notable candidates like AXS-05 for major depressive disorder, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. These therapies are being developed to provide novel treatment options where current solutions are limited or inadequate.

Axsome manages its business as a single operating segment, emphasizing the development and delivery of groundbreaking CNS therapies. The company has made significant strides in advancing its clinical programs, with several candidates progressing through various stages of clinical trials. Recent achievements include positive data readouts from clinical studies and successful end-of-phase meetings with regulatory bodies, positioning Axsome closer to potential market approvals.

Financially, Axsome maintains a solid foundation through strategic collaborations, public offerings, and partnerships. These financial maneuvers have enabled sustained investment in research and development, essential for driving innovation and bringing new therapies to market.

Axsome's commitment to transforming the treatment landscape for CNS disorders is underscored by its active engagement with the medical community, participation in scientific conferences, and continuous updates to investors and stakeholders. The company’s proactive communication strategy ensures transparency and keeps all interested parties informed about ongoing developments.

For the latest updates, investors and media can reach out to Mark Jacobson, Chief Operating Officer, or Darren Opland, Director of Corporate Communications, at Axsome's headquarters in New York City. More information is available on the company’s website, www.axsome.com.

Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) announced a settlement with Unichem Laboratories regarding patent litigation for Sunosi® (solriamfetol). The litigation arose after Unichem filed for FDA approval to market a generic version of Sunosi in the U.S. per an Abbreviated New Drug Application. The settlement allows Unichem to sell its generic version starting June 30, 2042, with possible earlier entry under specific conditions. Additionally, the date could be extended for pediatric exclusivity. The agreement will be reviewed by the U.S. Federal Trade Commission and the Department of Justice. Similar litigation with other parties continues in the District of New Jersey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) announced its participation in the American Migraine Foundation's efforts for Migraine & Headache Awareness Month in June 2024. This initiative aims to raise awareness about unmet treatment needs for the 37 million Americans suffering from migraines, which cause significant physical, emotional, and economic impacts. The American Migraine Foundation emphasizes the importance of education, support, community, and research to improve patient outcomes and societal attitudes toward migraines. Notably, 70% of migraine sufferers are dissatisfied with current treatments, and nearly 80% are open to trying new therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company specializing in central nervous system (CNS) disorders, announced its support for Alzheimer’s & Brain Awareness Month this June. The initiative aims to raise awareness about Alzheimer’s disease (AD), a progressive neurodegenerative disorder affecting nearly 7 million individuals in the U.S., a number that could double by 2060. Axsome's headquarters at One World Trade Center will be illuminated in purple on June 21, 2024, symbolizing AD awareness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company specializing in therapies for CNS disorders, announced participation in two investor conferences. These events include the William Blair 44th Annual Growth Stock Conference on June 5 in Chicago, where CEO Herriot Tabuteau, MD, will present a corporate overview, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12 in Miami Beach, where Axsome leadership will conduct investor meetings. A live webcast of the William Blair presentation will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
Rhea-AI Summary

On May 29, 2024, Axsome Therapeutics (NASDAQ: AXSM) announced significant findings on solriamfetol at the SLEEP 2024 conference, held from June 1-5, 2024, in Houston, Texas. The presentations highlighted solriamfetol's positive effects on cognitive function in patients with Obstructive Sleep Apnea (OSA) and narcolepsy, particularly those experiencing Excessive Daytime Sleepiness (EDS). Key findings from the SHARP study, led by Professor Hans Van Dongen, demonstrated improvements in executive function, memory, and processing speed. Presentations included two oral plenary sessions and multiple poster sessions, emphasizing solriamfetol's impact on various cognitive metrics and real-world applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
-
Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) will present data from its CNS disorder therapies at the American Society of Clinical Psychopharmacology Annual Meeting from May 28-31, 2024, in Miami Beach, Florida. Key presentations include:

1. Post-hoc analyses of Auvelity® demonstrating significant improvements in anhedonic and daily functioning in major depressive disorder (MDD) patients.

2. Data on AXS-05's clinical profile for treating Alzheimer's disease agitation, showcasing promising results from the Phase 2/3 development program.

3. Findings on Solriamfetol's efficacy in enhancing cognitive performance in sleep apnea patients from both preclinical and clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
Rhea-AI Summary

Axsome Therapeutics, Inc. (NASDAQ: AXSM) will be represented by Chief Executive Officer, Dr. Herriot Tabuteau, at two upcoming investor conferences. The company focuses on developing novel therapies for central nervous system disorders. The presentations will take place at the RBC Capital Markets 2024 Global Healthcare Conference on May 14 and the Bank of America 2024 Healthcare Conference on May 16. Investors can watch the events live on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
-
Rhea-AI Summary

Axsome Therapeutics reported strong financial results for the first quarter of 2024, with total net product revenue of $75.0 million, representing significant year-over-year growth. The company announced positive Phase 3 trial results for AXS-12 in narcolepsy, with other key pipeline programs progressing well. However, the increase in research and development expenses, higher selling, general, and administrative expenses, and a net loss of $68.4 million for the quarter are some challenges highlighted in the financial report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Axsome Therapeutics showcases its innovative neuroscience portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting, featuring data on AXS-05 in Alzheimer's disease agitation, AXS-07 in migraine, and solriamfetol's cognitive and wake promoting effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will report its financial results for Q1 2024 on May 6, 2024. The management team will discuss the results and provide a business update in a conference call at 8:00 a.m. Eastern Time. Participants can join via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
conferences earnings

FAQ

What does Axsome Therapeutics, Inc. do?

Axsome Therapeutics develops novel therapies for central nervous system (CNS) disorders with limited treatment options.

Where is Axsome Therapeutics based?

Axsome Therapeutics is headquartered in New York City, at One World Trade Center, 22nd Floor.

What are some key products in Axsome's pipeline?

Key products include AXS-05 for major depressive disorder, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.

What recent achievements has Axsome made?

Recent achievements include positive clinical trial data and successful regulatory meetings, advancing several pipeline candidates.

How does Axsome manage its business operations?

Axsome manages its business as one operating segment focused on developing and delivering CNS therapies.

How does Axsome maintain its financial health?

Axsome maintains its financial health through strategic collaborations, public offerings, and partnerships, ensuring sustained R&D investment.

Who are the key contacts for investors and media?

Investors can contact Mark Jacobson (COO), and media can contact Darren Opland (Director of Corporate Communications) at Axsome's headquarters.

What is the mission of Axsome Therapeutics?

Axsome's mission is to address unmet medical needs and improve the lives of patients suffering from CNS disorders.

What kind of disorders does Axsome focus on?

Axsome focuses on CNS disorders such as depression, migraine, narcolepsy, and Alzheimer's disease.

How can I stay updated on Axsome's latest news and developments?

You can stay updated by visiting Axsome's website or contacting their corporate communications team for the latest information.

Axsome Therapeutics, Inc.

Nasdaq:AXSM

AXSM Rankings

AXSM Stock Data

3.50B
34.88M
17.12%
83.32%
16.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK